Bollard Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$175M Sell
190,672
-7,548
-4% -$7.65M 5.17% 2
2025
Q4
$213M Sell
198,220
-9,085
-4% -$8.69M 5.32% 2
2025
Q3
$158M Sell
207,305
-44,184
-18% -$32.9M 3.72% 5
2025
Q2
$196M Buy
251,489
+11,346
+5% +$8.82M 4.48% 2
2025
Q1
$198M Buy
240,143
+248
+0.1% +$206K 5.21% 2
2024
Q4
$185M Sell
239,895
-11,628
-5% -$9.63M 5.13% 2
2024
Q3
$223M Sell
251,523
-63
-0% -$56.6K 5.93% 2
2024
Q2
$228M Buy
251,586
+237
+0.1% +$190K 6.43% 2
2024
Q1
$196M Buy
251,349
+259
+0.1% +$184K 5.91% 2
2023
Q4
$146M Buy
251,090
+296
+0.1% +$173K 5.09% 3
2023
Q3
$135M Buy
250,794
+306
+0.1% +$158K 4.96% 2
2023
Q2
$117M Buy
250,488
+203
+0.1% +$85.1K 4% 3
2023
Q1
$86M Buy
250,285
+548
+0.2% +$185K 3.1% 3
2022
Q4
$91.4M Sell
249,737
-7,016
-3% -$2.49M 3.49% 3
2022
Q3
$83M Buy
256,753
+200
+0.1% +$63.4K 3.49% 4
2022
Q2
$83.2M Buy
256,553
+505
+0.2% +$152K 3.37% 4
2022
Q1
$73.3M Buy
256,048
+2,297
+0.9% +$591K 2.35% 6
2021
Q4
$70.1M Buy
253,751
+746
+0.3% +$189K 2.24% 8
2021
Q3
$58.5M Buy
253,005
+1,327
+0.5% +$328K 1.91% 8
2021
Q2
$57.8M Sell
251,678
-21,690
-8% -$4.36M 1.83% 10
2021
Q1
$51.1M Sell
273,368
-24,560
-8% -$4.8M 1.79% 9
2020
Q4
$50.3M Sell
297,928
-1,919
-0.6% -$287K 1.87% 9
2020
Q3
$44.4M Sell
299,847
-2
-0% -$310 1.6% 9
2020
Q2
$49.2M Sell
299,849
-7,138
-2% -$1.1M 1.93% 6
2020
Q1
$42.6M Buy
306,987
+674
+0.2% +$92.6K 1.89% 6
2019
Q4
$40.3M Buy
306,313
+781
+0.3% +$90.5K 1.31% 11
2019
Q3
$34.2M Buy
305,532
+825
+0.3% +$91.8K 1.2% 14
2019
Q2
$33.8M Sell
304,707
-36,307
-11% -$4.28M 1.16% 12
2019
Q1
$44.3M Buy
341,014
+1,279
+0.4% +$156K 1.67% 8
2018
Q4
$39.3M Buy
339,735
+6,517
+2% +$728K 1.73% 6
2018
Q3
$35.8M Buy
333,218
+5,442
+2% +$544K 1.44% 7
2018
Q2
$28M Buy
327,776
+2,946
+0.9% +$242K 1.28% 10
2018
Q1
$25.1M Buy
324,830
+4,180
+1% +$337K 1.25% 9
2017
Q4
$27.1M Buy
320,650
+2,267
+0.7% +$193K 1.3% 10
2017
Q3
$27.2M Buy
318,383
+2,901
+0.9% +$238K 1.44% 7
2017
Q2
$26M Buy
315,482
+1,508
+0.5% +$123K 1.4% 5
2017
Q1
$26.4M Buy
313,974
+8,153
+3% +$653K 1.51% 4
2016
Q4
$22.5M Buy
305,821
+1,766
+0.6% +$132K 1.47% 4
2016
Q3
$24.4M Buy
304,055
+2,069
+0.7% +$166K 1.56% 4
2016
Q2
$23.8M Buy
301,986
+1,066
+0.4% +$80.3K 1.62% 4
2016
Q1
$21.7M Buy
300,920
+1,077
+0.4% +$81.5K 1.75% 5
2015
Q4
$25.3M Buy
299,843
+902
+0.3% +$74.9K 2.08% 4
2015
Q3
$25M Buy
298,941
+945
+0.3% +$79.8K 2.05% 4
2015
Q2
$24.9M Buy
297,996
+565
+0.2% +$43.1K 1.88% 6
2015
Q1
$21.6M Buy
297,431
+4,888
+2% +$348K 1.61% 8
2014
Q4
$20.2M Buy
292,543
+5,686
+2% +$384K 1.78% 8
2014
Q3
$18.6M Buy
286,857
+55,813
+24% +$3.53M 1.76% 7
2014
Q2
$14.4M Buy
231,044
+2,133
+0.9% +$127K 1.39% 9
2014
Q1
$13.5M Buy
228,911
+350
+0.2% +$19.5K 1.36% 10
2013
Q4
$11.7M Buy
228,561
+3,619
+2% +$181K 1.29% 11
2013
Q3
$11.3M Buy
224,942
+580
+0.3% +$30.4K 1.33% 11
2013
Q2
$11M Buy
+224,362
New +$12.2M 2.12% 10

Other funds holding LLY

Bollard Group's LLY Position: Q1 2026 in Review

Bollard Group reduced its Eli Lilly (LLY) stake by 3.8% in Q1 2026, selling an estimated $7.65M and leaving 190,672 shares worth $175M. The position accounts for 5.17% of the portfolio, ranked #2.

Bollard Group first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $228M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Bollard Group held 190,672 shares of Eli Lilly worth $175M as of Q1 2026.
  • Bollard Group sold 7,548 Eli Lilly shares in Q1 2026, an estimated $7.65M.
  • Eli Lilly made up 5.17% of Bollard Group's portfolio in Q1 2026, its #2 holding.
  • Bollard Group first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Bollard Group's Eli Lilly position peaked at $228M in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Bollard Group's 13F filing for Q1 2026, filed 14 May 2026.